Clinical trial
Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in…
NCT00132652 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00132652 |
|---|---|
| Title | Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B |
| Official title | A Randomized Trial of Switching Antiviral Therapy From Lamivudine to Telbivudine (LdT) vs. Continued Lamivudine Treatment in Adults With Chronic Hepatitis B |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis B |
| Intervention type | Drug |
| Interventions | Lamivudine, Telbivudine |
| Enrollment | 240 |
| Start date | Feb 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Aug 22, 2005 |
| Last update posted | Feb 23, 2017 |
| Countries | Australia, Canada, China, France, Israel, New Zealand, Singapore, Taiwan, Thailand, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: